drf-1042

DRF-1042 is an orally active small molecule derivative of camptothecin that functions as a DNA topoisomerase I inhibitor. It has demonstrated strong anticancer activity in vitro against a range of human cancer cell lines, including those with multi-drug resistance phenotypes. The drug was initially developed by Dr. Reddy's Laboratories and has been investigated primarily for the treatment of solid tumors and other neoplasms. Its mechanism of action involves inhibition of DNA topoisomerase I, leading to disruption of DNA replication and transcription in cancer cells[1][4][5][8].

Other names

5-(2'-Hydroxyethoxy)-20(S)-camptothecinUNII-461WVF206PUNII461WVF206PUNII 461WVF206P(4S)-4-Ethyl-4-hydroxy-12-(2-hydroxyethoxy)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione